A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 09 May 2025
At a glance
- Drugs Guselkumab (Primary) ; Guselkumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms QUASAR
- Sponsors Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
Most Recent Events
- 05 May 2025 Results presented in the Johnson & Johnson Media Release.
- 05 May 2025 According to a Johnson & Johnson media release, company presented result data from this study at Digestive Disease Week (DDW) 2025.
- 25 Apr 2025 According to a Johnson & Johnson media release, based on data from QUASAR programme, the European Commission (EC) has approved a Marketing Authorisation (MA) for TREMFYA (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.